The International Agency for Research on Cancer reported that infections were responsible for 2.3 million new cancer cases in 2024, representing 12% of all global cancer diagnoses. Helicobacter pylori, HPV, hepatitis B and C, and Epstein-Barr virus were the primary infectious causes.
GSK reported that its experimental chronic hepatitis B drug helped nearly one in five patients achieve a functional cure in late-stage studies, vastly outpacing current treatments and raising hopes for a finite treatment course as an alternative to lifelong therapy.
Multiple new studies project that delaying hepatitis B vaccination after birth—as recommended in new U.S. policy that offers the vaccine only to at-risk infants—will lead to increased infections, decreased survival rates, and lifelong health complications among newborns.